Drug Profile
Research programme: cancer therapeutics - Ferrer/Vivia Biotech
Alternative Names: Cancer therapy - Ferrer/Vivia Biotech; FIB 114; Onco-therapy - Ferrer/Vivia BiotechLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Ferrer; Vivia Biotech
- Developer Ferrer
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 16 Jan 2019 DC/MoA project: the product is no longer available on either of the company websites, and from the introduction its not clear if they were developing it as a cell therapy, hence removed DC "Cell-therapies, Gene-therapies" and added "antineoplastics"
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Spain (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Spain (Parenteral)